Cognition Therapeutics Inc.
2403 Sidney Street
Suite 261
Pittsburgh
Pennsylvania
15203
United States
Tel: 412-481-2210
Fax: 412-481-2216
Website: http://www.cogrx.com/
Email: info@cogrx.com
121 articles about Cognition Therapeutics Inc.
-
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
3/15/2024
Cognition Therapeutics, Inc. today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, March 26, 2024 before the market open.
-
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
3/14/2024
Cognition Therapeutics, Inc., a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced the closing of its previously announced underwritten public offering of 6,571,428 shares of its common stock.
-
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
3/12/2024
Cognition Therapeutics, Inc. announced that it has priced an underwritten public offering of 6,571,428 shares of its common stock at an offering price of $1.75 per share of common stock.
-
Cognition Therapeutics Announces Proposed Public Offering of Common Stock - March 11, 2024
3/11/2024
Cognition Therapeutics, Inc., a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that it has commenced an underwritten public offering of shares of its common stock.
-
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
3/6/2024
Cognition Therapeutics, Inc. is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal).
-
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
2/26/2024
Cognition Therapeutics, Inc. announced today that the Company’s president and CEO, Lisa Ricciardi will present at the TD Cowen 44th Annual Health Care Conference taking place March 4-6, 2024.
-
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
2/6/2024
Cognition Therapeutics, Inc. announced that collaborators at the University of Edinburgh, Scotland published findings in the journal, Acta Neuropathologica, that provide new insight into the biology of Alzheimer’s disease that is consistent with our understanding of the role the σ-2 receptor has in regulating Aβ oligomer binding.
-
Cognition Therapeutics CEO Issues Letter to Shareholders
1/4/2024
Cognition Therapeutics, Inc. today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024.
-
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
11/16/2023
Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its seventh Conversations video podcast episode: “Quantitative EEG - Effects of CT1812 on Measures of Synaptic Function in Alzheimer’s Disease.”
-
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
11/15/2023
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is presenting in vivo preclinical results at the Society for Neuroscience’s annual meeting illuminating the role of sigma-2 (σ-2) receptor modulators, including CT1812, in models of Alzheimer's and Parkinson’s diseases.
-
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
11/7/2023
Cognition Therapeutics, Inc. today announced that the last participant was randomized in the Phase 2 SHINE study ( NCT03507790 ) of CT1812, the company’s lead candidate for the treatment of age-related neurodegenerative diseases of the CNS and retina.
-
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
11/2/2023
Cognition Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023 and provided recent business updates.
-
Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD
10/27/2023
Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that Christoper van Dyck, M.D., the director of the Yale Alzheimer's Disease Research Unit and the Yale Alzheimer's Disease Research Center, is presenting the Phase 2 study design of the company’s ongoing START study in an oral late-breaking session at Clinical Trials on Alzheimer’s Disease (CTAD) conference.
-
Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
10/24/2023
Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced that Willem de Haan, M.D., Ph.D., a neurologist and senior researcher at the Amsterdam University Medical Centers’ Alzheimer Center, is presenting complete EEG findings from the Phase 2 SEQUEL study at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator.
-
Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications
10/16/2023
Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced upcoming presentations from studies of CT1812, the Company's lead candidate for the treatment of adults with early, mild and moderate Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease (CTAD) conference being held October 24-27, 2023 virtually and in person in Boston, MA.
-
Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD
9/7/2023
Cognition Therapeutics, Inc., has released its sixth “Conversations” video podcast, which features an interactive discussion with retinal specialists about dry age-related macular degeneration and the current treatment landscape.
-
Cognition Therapeutics Announces Participation in Upcoming September 2023 Conferences
8/30/2023
Cognition Therapeutics, Inc. announced that Lisa Ricciardi, Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright Annual Global Investment Conference and participating on a panel at the Cantor Fitzgerald Global Healthcare Conference in September 2023.
-
Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023
8/2/2023
Cognition Therapeutics, Inc. today announced that the Company will release financial results for the second quarter on Tuesday, August 8, 2023 before the market opens.
-
Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
7/11/2023
Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has dosed the first participant in the Phase 2 MAGNIFY study of CT1812, an experimental therapy being developed for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).
-
Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease
7/5/2023
Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that the first clinical trial site has been activated and can begin recruiting participants for the 540-patient Phase 2 START study of CT1812 in adults with early Alzheimer’s disease.